Home › Employers › Dispatch Biotherapeutics, Inc.
Dispatch Biotherapeutics, Inc.: H-1B salaries and sponsorship
Dispatch Biotherapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $118,450.
Does Dispatch Biotherapeutics, Inc. sponsor H-1B visas?
Dispatch Biotherapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 22, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Scientist I – Platform Discovery | 1 | $100,000 |
| Scientist III, Preclinical Candidate Development | 1 | $152,000 |
| Scientist II | 1 | $118,450 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 2 | $126,000 |
| FY2025 | 1 | $118,450 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Scientist II | $118,450 Level III | Philadelphia, PA | Apr 22, 2025 | Oct 1, 2025 | Certified |
| Scientist III, Preclinical Candidate Development | $152,000 Level III | San Francisco, CA | May 16, 2024 | Jun 17, 2024 | Certified |
| Scientist I – Platform Discovery | $100,000 Level III | Philadelphia, PA | Oct 24, 2023 | Nov 15, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).